1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer

• Cheng Liu,
• Sarah Stevens,
• Heleen Roose,
• Kha Le,
• Kristina Rekstyte-Matiene,
• Kusum Gupta,
• Sandra Chang,
• Vladimir Serebryany,
• Lillian Adame,
• Antitsa Stoycheva,
• Lawrence M Blatt,
• Leonid Beigelman,
• Sushmita Chanda,
• David B Smith,
• Julian A Symons,
• Andreas Jekle,
• Tongfei Wu

Affiliations

Cheng Liu

Faculty of Medicine, The University of Queensland, Saint Lucia, Queensland, Australia

Sarah Stevens

Department of Anaesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Heleen Roose

Oncurious NV, Leuven, Belgium

Kha Le

2Genentech Inc., South San Francisco, California, USA

Kristina Rekstyte-Matiene

1Aligos Belgium BV, Leuven, Vlaams-Brabant, Belgium

Kusum Gupta

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Sandra Chang

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Vladimir Serebryany

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Lillian Adame

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Antitsa Stoycheva

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Lawrence M Blatt

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Leonid Beigelman

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Sushmita Chanda

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

David B Smith

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Julian A Symons

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Andreas Jekle

2Aligos Therapeutics, Inc., South San Francisco, CA, USA

Tongfei Wu

1Aligos Belgium BV, Leuven, Vlaams-Brabant, Belgium